Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
Randomized-controlled trial and microbiome assessment to understand the risk-to-benefit ratio
of prophylactic antibiotics (Ceftriaxone) vs placebo in patients with pneumonia and
inflammation after cardiac arrest outside the hospital.
Phase:
Phase 2
Details
Lead Sponsor:
David J. Gagnon
Collaborators:
MaineHealth National Institute of General Medical Sciences (NIGMS) University of New England